Tuesday, February 20, 2018

Tuesday, 19 September 2017 Divani Caravel Hotel

George Vassilopoulos

MD PhD, Professor of Hematology, University of Thessaly Medical School, Head, Division of Hematology Larisa University Hospital, Affiliate Investigator, Group Leader Cell and Gene Therapy Lab BRFAA, Athens

George Vassilopoulos
George Vassilopoulos

Dr Vassilopoulos is a Professor of Hematology (U of Thessaly Medical School) and an Affiliate member of BRFAA (Group Leader, Genetics and Gene Therapy Lab). He has earned his MD and PhD degrees from the University of Athens Medical School and a MSc degree in Hematology from the Royal Postgraduate Medical School, UCL.

His research interest is on genetic interventions on Hematopoietic stem cell (HSC) for the correction of inherited disorders. In his PhD years and later as a post-doctoral fellow in the US (Div. of Medical Genetics, UW), he studied globin gene regulation and HSC biology.

For HSC marking experiments, he focused on the development of Foamy Virus (FV) vectors and showed that the vectors can transduce murine and human HSC; he then used the FV technology to dissect the mechanism of HSC plasticity i.e. the HSC potential to derive non-hematopoietic tissues. His work culminated in the description of cell-fusion as the mechanism underlying the change of fates observed in HSC development.

In the BRFAA lab, he developed therapeutic FV vectors b-thalassemia and chronic granulomatous disease; in addition he developed vectors capable of delivering siRNA, vectors expressing two cDNA in a coordinated fashion and vectors for iPSCs production. As a clinical scientist, he has focused in the dissection of tumor-initiating cells in leukemia and neuroblastoma. We have studied the role of the Wnt signaling in the development of leukemia and the role of CD44 in neurobalstoma.

Another area of research invloves the dissection of the role of MyD88, in lymphoma development; we have found a strong association between MyD88 haplotypes and risk of Hodgkin’s lymphoma while in a collaborative study, a strong association has emerged between sarcoidosis and TB with certain MyD88 haplotypes. Currently, we have focused in the developemnt of FV vectors harboring CARs for the initial production of anti-CD19 CAR-T cells.

International speakers

Jan Geissler Jan Geissler is founder and managing director of Patvocates, acting as advisor on patient advocacy, health policy and social media. From 2012-2017, he has been the Director of the 'European Patients Academy' (EUPATI), which has developed education about medicines development processes. He is now coordinating the team that takes change of the evolution of EUPATI.
Peter Hohenberger Peter Hohenberger, MD, is Head of the Division of Surgical Oncology and Thoracic Surgery at the Medical Faculty Mannheim, University of Heidelberg (UMM). He is a boarded surgeon in visceral and vascular surgery as well as in thoracic surgery and surgical intensive care.
Panos Kanavos Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Associate Professor in International Health Policy in the Department of Social Policy, London School of Economics (LSE), Deputy Director at LSE Health, and Programme Director of the Medical Technology Research Group (MTRG) at LSE Health.
Annalisa Trama Dr. Annalisa Trama graduated cum laude in Medicine and Surgery from the University of Rome "La Sapienza"(1993-1999). She obtained her Master’s in health services/system research from London School of Hygiene and Tropical Medicine (2001-2002), she specialized in Public Health from University “La Sapienza”– Rome (1999-2003). She obtained her PhD in Public Health from University “La Sapienza”– Rome (2004-2006).

© 2018 Boussias Communications, all rights reserved. info@boussias.com, T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team